Dr Reddy’s drug-free migraine management device, Nerivio launched in Europe: How it works

Dr Reddy’s Laboratories, a pharmaceutical company, launched Nerivio, its migraine management device in India last year. The company has now launched the device in Europe.
Nerivio is approved by the United States Food and Drug Administration (USFDA), and is CE-mark certified in Europe. Migraine is a global health challenge, affecting around 30% of adults on 15 or more days per month, impacting 1.7% to 4% of the population.
The current best estimate of global migraine prevalence is 14–15%, and, in terms of burden, migraine accounts for 4.9% of global ill health, quantified as years lived with disability. Around 8 to 10 million people in Germany are affected, 14.8% of women and 6.0% of men.
Nerivio, a prescription-based, non-invasive solution, is designed to address both acute and preventive treatment of migraines. Worn on the upper arm, each Nerivio device offers 18 sessions lasting 45 minutes each. For acute migraine treatment, it’s recommended to use within 60 minutes of headache onset, while for preventive measures, it can be used every other day.
The company asserts that Nerivio operates through Remote Electrical Neuromodulation (REN), targeting nerve endings to trigger conditioned pain modulation. This stimulation initiates a natural process of pain relief in the brainstem, resulting in widespread pain inhibition that targets the root cause of migraine discomfort in the head.
The Nerivio migraine treatment device is accompanied by the Nerivio app, accessible on both Android and iOS platforms. This app allows users to adjust the device’s intensity levels and includes an interactive migraine diary for symptom logging, response tracking, and sharing valuable analytics.
Source: Indiatimes